3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
5
Recruiting
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Hodgkin Disease
6
Sarcoma
3
Melanoma
2
Leiomyosarcoma
2
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Melanoma, Cutaneous Malignant
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Hyperthermia
1
Advanced Melanoma
1
Interventions
Specimen Handling
4
Gemcitabine
3
Doxorubicin
3
liposomal doxorubicin
2
Trabectedin
2
Magnetic Resonance Spectroscopy
2
Dacarbazine
2
Biopsy
2
toripalimab
1
regorafenib
1
peposertib
1
cemiplimab
1
anlotinib
1
abemaciclib
1
X-Rays
1
Tretinoin
1
Tissue Banks
1
Tablets
1
Surgical Procedures, Operative
1
Standard of Care
1
Rosuvastatin Calcium
1
Radiotherapy
1
Quality of Life
1
Nivolumab
1
Neoadjuvant Therapy
1
Midazolam
1
Injections
1
Immunoglobulin G
1
Ifosfamide
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Leiomyosarcoma
×
Dacarbazine
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled
NCT04535271
2025-02-24
TAGGED
Sarcoma Oncology Research Center, LLC
Phase 2
Recruiting
80 enrolled